Related Experiment Videos
OK-432 therapy for cervical lymphangioma
Jean-Yves Sichel1, Raphael Udassin, David Gozal
1Department of Otolaryngology/Head and Neck Surgery, The Hebrew University School of Medicine-Hadassah Medical Center, Jerusalem, Israel.
The Laryngoscope
|September 30, 2004
Summary
Intralesional OK-432 injections effectively treat head and neck lymphangiomas with no complications. This sclerosing therapy is a viable alternative to surgery, even if surgery is needed later.
Area of Science:
- Head and Neck Surgery
- Pediatric Surgery
- Interventional Radiology
Background:
- Lymphangiomas, particularly macrocystic types in the head and neck, present treatment challenges.
- Surgical excision is a common treatment but can be associated with complications and fibrosis.
- Minimally invasive treatment options are sought to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of intralesional OK-432 as a sclerosing agent for head and neck lymphangiomas.
- To assess the impact of OK-432 treatment on subsequent surgical interventions, if required.
Main Methods:
- A case series involving 11 patients (7 children, 4 adults) with macrocystic cervical lymphangiomas.
- Treatment consisted of one to three ultrasound-guided intralesional injections of OK-432.
- Dosage was standardized, with sedation used for pediatric patients.
Main Results:
- Complete or subcomplete resolution was achieved in 73% of patients after one or two OK-432 injections.
- No complications were observed during or after OK-432 injections.
- In cases requiring surgery, no significant fibrosis was noted, indicating preserved surgical options.
Conclusions:
- Intralesional OK-432 is an effective and safe sclerosing treatment for macrocystic lymphangiomas in the head and neck.
- The absence of complications and fibrosis makes OK-432 a valuable option to consider before surgical excision.
- This approach offers a less invasive alternative with favorable outcomes.